SCHEMBL5458319

SCHEMBL5458319

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2NCc1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.46
ALDH1A1 P00352 5/20 0.40
HPGD P15428 2/20 0.40
MDM2 Q00987 1/20 0.40
MAPT P10636 5/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
MAPK10 P53779 2/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPC1 O15118 1/20 0.38
IKBKB O14920 2/20 0.37
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TNIK Q9UKE5 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451709 0.81 FLT3 (0.41) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5455200 0.78 FLT3 (0.46) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5457860 0.77 FLT3 (0.44) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5453191 0.76 KMT2A (0.45) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5459168 0.76 FLT3 (0.40) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5450745 0.76 FLT3 (0.46) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5454125 0.76 FLT3 (0.43) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5457867 0.75 KMT2A (0.46) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5451643 0.74 FLT3 (0.55) FLT3ALDH1A1HPGDMDM2MAPT
SCHEMBL5458311 0.72 FLT3 (0.52) FLT3ALDH1A1HPGDMDM2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885HPGD 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.